Biomarker discovery for autoimmune disorders
We have identified a novel biomarker that shows great promise as an inflammatory biomarker for autoimmune disorders. This biomarker is notably overexpressed in patients with Systemic Lupus Erythematosus (SLE) compared to control groups. Building on this discovery, we are actively pursuing research to examine the presence and levels of this biomarker across various autoimmune biobanks (Rheumatoid arthritis (RA), Takayasu’s arteritis, Antineutrophilic cytoplasmic antibody (ANCA), Polyarteritis Nodosa (PAN) , Multiple Sclerosis (MS), etc.) and in the context of infectious diseases. Our goal is to understand the broader applications of this biomarker and to potentially establish a new routine test, which will potentially outperform to current test (CRP) in autoimmune disease in terms of specificity.